Prostate Cancer Specific Mortality In The Erspc Trial: What Is The Role Of Screening Result And Adherence

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I (PD13)1 Sep 2021PD13-04 PROSTATE CANCER SPECIFIC MORTALITY IN THE ERSPC TRIAL: WHAT IS THE ROLE OF SCREENING RESULT AND ADHERENCE Christian Wetterauer, Sebastiaan Remmers, Lukas W. Prause, Jonas Hugosson, Teuvo L.J. Tammela, Marco Zappa, Vera Nelen, Marcos Lujan, Louis J. Denis, Alvaro Paez, Donella Puliti, Arnauld Villers, Xavier Rebillard, Rebecka Arnsrud Godtman, Chris Bangma, Fritz H. Schröder, Anssi Auvinen, Lukas Manka, Helge H Seifert, Stephen F. Wyler, Monique J Roobol, and Maciej Kwiatkowski Christian WetterauerChristian Wetterauer More articles by this author , Sebastiaan RemmersSebastiaan Remmers More articles by this author , Lukas W. PrauseLukas W. Prause More articles by this author , Jonas HugossonJonas Hugosson More articles by this author , Teuvo L.J. TammelaTeuvo L.J. Tammela More articles by this author , Marco ZappaMarco Zappa More articles by this author , Vera NelenVera Nelen More articles by this author , Marcos LujanMarcos Lujan More articles by this author , Louis J. DenisLouis J. Denis More articles by this author , Alvaro PaezAlvaro Paez More articles by this author , Donella PulitiDonella Puliti More articles by this author , Arnauld VillersArnauld Villers More articles by this author , Xavier RebillardXavier Rebillard More articles by this author , Rebecka Arnsrud GodtmanRebecka Arnsrud Godtman More articles by this author , Chris BangmaChris Bangma More articles by this author , Fritz H. SchröderFritz H. Schröder More articles by this author , Anssi AuvinenAnssi Auvinen More articles by this author , Lukas MankaLukas Manka More articles by this author , Helge H SeifertHelge H Seifert More articles by this author , Stephen F. WylerStephen F. Wyler More articles by this author , Monique J RoobolMonique J Roobol More articles by this author , and Maciej KwiatkowskiMaciej Kwiatkowski More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001989.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: With a median follow–up of 16 years the European Randomized Study of Screening for Prostate Cancer (ERSPC) shows a relative reduction of prostate cancer (PCa) specific mortality (PCSM) of 20% in favour of prostate-specific antigen (PSA) based screening. However, despite screening 520 men died from PCa. METHODS: This multicentre population-based randomised screening trial in eight European countries has included a total of 182 160 men. Here we provide descriptive analyses and visualizations of the screening history and outcome data of men who died of PCa in the ERSPC. RESULTS: A total of 1313 men died of PCa in the ERSPC. 793 (60%) men had been randomised to the control arm and 520 (40%) to the screening arm. 137/520 (26 %) participants randomised to screening never attended (Group A). 218/520 (42 %) participants had an initial positive screening (i.e., recommendation for biopsy) (Group B). 117/520 (23%) participants had at least one negative screening and did not follow up or had a positive screen (Group C) and 48/520 (9%) participants completed the screening with negative screening and were diagnosed with PCa later in time (Group D). Median (IQR) age at death for the groups A-D was 72 years (69-77), 73 years (69-77), 74 years (70-78) and 75.5 years (70-80), respectively. The rate of M+ disease at diagnosis was 5% for Group A, 12% for Group B, 29% for Group C, and 52% for Group D. CONCLUSIONS: This study analyses all cases of PCSM in a large screened European population and describes scenarios in which screening failed. Adherence to screening was identified as most important contributing factors for success or failure of a screening protocol, reflected by the percentage of M+ disease. In addition, men who completed screening with negative screenings in all rounds and died of prostate cancer should be classified as failure of screening protocol. These data should help in development and refinement of the future screening policy for PCa. Source of Funding: © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e210-e211 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian Wetterauer More articles by this author Sebastiaan Remmers More articles by this author Lukas W. Prause More articles by this author Jonas Hugosson More articles by this author Teuvo L.J. Tammela More articles by this author Marco Zappa More articles by this author Vera Nelen More articles by this author Marcos Lujan More articles by this author Louis J. Denis More articles by this author Alvaro Paez More articles by this author Donella Puliti More articles by this author Arnauld Villers More articles by this author Xavier Rebillard More articles by this author Rebecka Arnsrud Godtman More articles by this author Chris Bangma More articles by this author Fritz H. Schröder More articles by this author Anssi Auvinen More articles by this author Lukas Manka More articles by this author Helge H Seifert More articles by this author Stephen F. Wyler More articles by this author Monique J Roobol More articles by this author Maciej Kwiatkowski More articles by this author Expand All Advertisement Loading ...